Targeting platelet-derived CXCL12 impedes arterial thrombosis

Area of Science:

• Cardiovascular Biology
• Thrombosis Research
• Drug Discovery

Background:

• Arterial thrombosis presents significant clinical challenges, necessitating novel therapeutic targets.
• Understanding molecular mechanisms of platelet aggregation is crucial for developing improved treatments.
• Chemokine CXCL12 and its receptor CXCR4 play a role in platelet activation.

Purpose of the Study:

• To investigate the role of platelet-derived CXCL12 in arterial thrombosis.
• To evaluate the therapeutic potential of inhibiting the CXCL12-CXCR4 axis.
• To explore novel peptide-based inhibitors for atherothrombosis.

Main Methods:

• Inhibition of CXCR4 using specific antagonists.
• Assessment of platelet aggregation under static and arterial flow conditions.
• Evaluation of arterial thrombosis and neointimal lesion formation in mouse models.
• Mechanistic studies involving Bruton's tyrosine kinase (Btk) and integrin signaling.
• Development and testing of a novel peptide inhibitor, i[VREY]4.

Main Results:

• CXCR4 inhibition attenuated collagen- and plaque homogenate-induced platelet aggregation.
• Platelet-specific CXCL12 deficiency reduced arterial thrombosis and neointimal hyperplasia without affecting bleeding time.
• CXCL12-CXCR4 signaling activates Btk, leading to integrin αIIbβ3 activation and platelet aggregation.
• The peptide i[VREY]4 inhibited Btk activation and platelet aggregation, preventing thrombosis.
• i[VREY]4 did not prolong in vitro bleeding time, unlike standard antiplatelet drugs.

Conclusions:

• Platelet-derived CXCL12 contributes to arterial thrombosis.
• Targeting the CXCL12-CXCR4-Btk axis is a promising strategy for treating atherothrombosis.
• The peptide i[VREY]4 demonstrates therapeutic potential as a novel antiplatelet agent with an improved safety profile.